Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377803 · ClinicalTrials.gov registry record · Phase 3
Cantharidin Application in Molluscum Patients
A Phase 3 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 262
- Enrollment target
NCT03377803: Completed Phase 3 study, sponsored by Verrica Pharmaceuticals.
NCT03377803 is a Phase 3 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 262 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03377803, a Phase 3 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 262 participants
- Enrollment target
Study Summary
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy will be assessed as the proportion of subjects achieving complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit.
Primary Outcome
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
Interventions
- COMBINATION_PRODUCT VP-102 - Cantharidin, Topical Film Forming Solution
- COMBINATION_PRODUCT Placebo -Topical Film Forming Solution without VP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 3 |
What the finished NCT03377803 record still lists
NCT03377803 is an interventional study that assigns participants to a tested intervention. The registered 262 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which VP-102 - Cantharidin, Topical Film Forming Solution is the first listed.
NCT03377803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03377803 about?
NCT03377803 is a clinical study titled "Cantharidin Application in Molluscum Patients". This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagio...
What is the current status of trial NCT03377803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 262 participants. The study started on 2018-02-14. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03377803?
The interventions under investigation include: VP-102 - Cantharidin, Topical Film Forming Solution (COMBINATION_PRODUCT), Placebo -Topical Film Forming Solution without VP-102 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03377803?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03377803's enrollment target sits among peer trials
262 1228th of 2000 higher than 773 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
- NCT06780137 · 262 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI